Capmatinib | Memorial Sloan Kettering Cancer Center
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
TABRECTA® (capmatinib) tablets | Health Care Providers
SAFETY, DOSING, AND ADMINISTRATION
PDF) Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP)
Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non–Small-Cell Lung Cancer | JCO Precision Oncology
Novartis Rahika Capmatinib, Box at Rs 75000/box in Mumbai | ID: 26152999862
capmatinib
Dosing & Administration | TABRECTA® (capmatinib) tablets
213591Orig1s000
Tabrecta (capmatinib) for the Treatment of Non-Small Cell Lung Cancer
Capmatinib (INC280) | c-MET Kinase Inhibitor | MedChemExpress
capmatinib (Tabrecta™)
Schematic representation of MET signaling blockade by capmatinib.... | Download Scientific Diagram
TABRECTA Dosage & Rx Info | Uses, Side Effects
Tabrecta (capmatinib)
Tabrecta (capmatinib)
TABRECTA® (capmatinib) tablets | Health Care Providers
Tabrecta (Capmatinib) Approved for Patients with Metastatic NSCLC and MET Exon 14 Skipping Mutation | Oncology Practice Management
PDF) Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts
Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts - Bang - 2020 - Cancer Science - Wiley Online Library
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies - Cancer Treatment Reviews
2 Synopsis
Capmatinib Tablets
